02.17.12
Robert Gwozdz has been appointed director of oral formulation at Particle Sciences, Inc. (PSI). Mark Mitchnick, chief executive officer of PSI, said, “PSI has a broad array of drug delivery technologies applicable across many dosage forms and drug types. About 25% of our work is on oral products. The client base now warrants a dedicated director for oral product development. Robert has a vast amount of experience having come from the generics industry and having been key on approximately 30 ANDAs.”
Mr. Gwozdz said, “Having been with one of the largest generic companies, I have had the luxury of exposure to virtually every current delivery strategy. I’m really looking forward to leveraging PSI’s technology portfolio for both new chemical entities and life-cycle extension challenges. The approaches to both these challenges have substantially merged over the last few years and PSI is perfectly positioned to leverage this.”
Mr. Gwozdz said, “Having been with one of the largest generic companies, I have had the luxury of exposure to virtually every current delivery strategy. I’m really looking forward to leveraging PSI’s technology portfolio for both new chemical entities and life-cycle extension challenges. The approaches to both these challenges have substantially merged over the last few years and PSI is perfectly positioned to leverage this.”